Skip to main content
Midas Edge

Amphastar Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Feb 29, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 29, 2024

AMPH$29.06-1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · Common Stock · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · Treasury Stock · ​ · Total · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Other · ​ · ​ · ​ · ​ · ​ · ​ · Amphastar · ​ · Non- · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Paid-in · ​ · Retained · ​ · Comprehensive · ​ · ​ · ​ · ​ · ​ · ​ · Stockholders' · ​ · controlling · ​ · ​ · ​
​ · ​ · Shares · ​ · Amount · ​ · Capital · ​ · Earnings · ​ · Income (loss) · ​ · Shares · ​ · Amount · ​ · Equity · ​ · Interest · ​ · Total
Balance as of December 31, 202054,760,922​$5​$410,061​$117,773​$(3,721)(7,265,483)​$(121,812)​$402,306​$46,417​$448,723​
Net income attributable to Amphastar Pharmaceuticals, Inc.—​—​—​62,116​——​—​62,116​—​62,116​
Other comprehensive loss attributable to Amphastar Pharmaceuticals, Inc.—​—​—​—​(2,682)—​—​(2,682)​—​(2,682)​
ANP restructuring (see Note 3)​—​​—​​(22,162)​​448​​(362)​—​​—​​(22,076)​​(46,641)​​(68,717)​
Net income attributable to non-controlling interest​—​​—​​—​​—​​—​—​​—​​—​​1,185​​1,185​
Purchase of treasury stock—​—​—​—​—(1,477,305)​​(28,873)​​(28,873)​​—​(28,873)​
Issuance of treasury stock in connection with the Company's equity plans​—​—​(206)​—​—17,498​​206​​—​​—​—​
Issuance of common stock in connection with the Company's equity plans1,679,280​1​15,924​—​——​—​15,925​—​15,925​
Share-based compensation expense—​—​18,806​—​——​—​18,806​(961)​17,845​
Balance as of December 31, 202156,440,202​$6​$422,423​$180,337​$(6,765)(8,725,290)​$(150,479)​$445,522​$—​$445,522​
Net income attributable to Amphastar Pharmaceuticals, Inc.—​—​—​91,386​——​—​91,386​—​91,386​
Other comprehensive loss attributable to Amphastar Pharmaceuticals, Inc.—​—​—​—​(1,859)—​—​(1,859)​—​(1,859)​
Purchase of treasury stock—​—​—​—​—(1,335,528)​​(39,909)​​(39,909)​​—​(39,909)​
Issuance of treasury stock in connection with the Company's equity plans​—​—​(864)​—​—62,656​​864​​—​​—​—​
Issuance of common stock in connection with the Company's equity plans1,670,029​—​15,658​—​——​—​15,658​—​15,658​
Share-based compensation expense—​—​17,860​—​——​—​17,860​—​17,860​
Balance as of December 31, 202258,110,231​$6​$455,077​$271,723​$(8,624)(9,998,162)​$(189,524)​$528,658​$—​$528,658​
Net income attributable to Amphastar Pharmaceuticals, Inc.—​—​—​137,545​——​—​137,545​—​137,545​
Other comprehensive loss attributable to Amphastar Pharmaceuticals, Inc.—​—​—​—​146—​—​146​—​146​
Purchase of treasury stock—​—​—​—​—(1,338,757)​​(58,144)​​(58,144)​​—​(58,144)​
Issuance of treasury stock in connection with the Company's equity plans​—​—​(237)​—​—15,606​​237​​—​​—​—​
Issuance of common stock in connection with the Company's equity plans1,279,963​—​10,974​—​——​—​10,974​—​10,974​
Share-based compensation expense—​—​20,242​—​——​—​20,242​—​20,242​
Balance as of December 31, 202359,390,194​$6​$486,056​$409,268​$(8,478)(11,321,313)​$(247,431)​$639,421​$—​$639,421​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.